AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2209383 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 172
Study 7324833 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine (0.3 mg)
Number of subjects: 20
Study 7324833 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone (10 mg)
Number of subjects: 20
Study 30777086 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7594 800 μg
Number of subjects: 54
Study 30777086 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7594 250 μg
Number of subjects: 54
Study 30777086 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7594 58 μg
Number of subjects: 54
Study 30777086 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of AZD7594
Number of subjects: 54
Study 30777086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29103052 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine as a disease modifying agent for PD
Number of subjects: 336
Study 29103052 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including multi-modal outreach and protocol modifications
Number of subjects: 336
Study 29103052 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral sources for recruitment
Number of subjects: 336
Study 25827292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (intraoperative nasojejunal tube placement and enteral feeding until adequate oral intake could be maintained)
Number of subjects: 109
Study 25827292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 109
Study 25827292 — intervention group
Group type: COMPARATOR
Intervention: Standard care (postoperative diet as tolerated)
Number of subjects: 109
Study 25827292 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 109
Study 25798509 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-SD (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 43
Study 25798509 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 21059817 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0, 10, 20, and 40 mg)
Number of subjects: 11
Study 21059817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18793861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 75
Study 18793861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 75
Study 18793861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study 17530638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg/day)
Number of subjects: 24
Study 17530638 — intervention group
Group type: COMPARATOR
Intervention: Control (no bosentan treatment)
Number of subjects: 24
Study 15238592 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg of isoflavones (25.6 g daily for 12 months)
Number of subjects: 202
Study 15238592 — intervention group
Group type: COMPARATOR
Intervention: Total milk protein as a powder (placebo)
Number of subjects: 202
Study 12166512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 51
Study 12166512 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (untreated patients)
Number of subjects: 51
Study 12166512 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 51
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological outreach programmes
Number of subjects: 14
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapies
Number of subjects: 14
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 14
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions with more female participants
Number of subjects: 14
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions offering more sessions
Number of subjects: 14
Study 9489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 14
Study 8194505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc with 600 mg elemental calcium as calcium carbonate
Number of subjects: 9
Study 8194505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc with 600 mg elemental calcium as calcium citrate
Number of subjects: 9
Study 8194505 — intervention group
Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 9
Study 8194505 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 9
Study 8194505 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 9
Study 3651528 — intervention group
Group type: EXPERIMENTAL
Intervention: RS 86 (oral, long-acting muscarinic agonist)
Number of subjects: 12
Study 3651528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31030965 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated silicone Foley catheters
Number of subjects: 54
Study 31030965 — intervention group
Group type: COMPARATOR
Intervention: Normal silicone Foley catheters
Number of subjects: 54
Study 27900813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane at 1 l·min‐1 fresh gas flow [O2 : N2 O = 50 : 50]
Number of subjects: 50
Study 27900813 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow reduced to 0.5 l·min‐1 [O2 : N2 O = 50 : 50] (control group)
Number of subjects: 50
Study 25840693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg, intravenous infusions every 3 weeks for four doses, then every 3 months for up to 3 years)
Number of subjects: 951
Study 25840693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study 23838728 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 47
Study 21667450 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychoanalytic treatment
Number of subjects: 28
Study 21667450 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 28
Study 19491826 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin for 7 days
Number of subjects: 144
Study 19491826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 16776756 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile .04 taper rotary instruments
Number of subjects: 60
Study 16776756 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic Endodontic Technology (AET)
Number of subjects: 60
Study 16776756 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation with Hedström files
Number of subjects: 60
Study 12766064 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGTS VF score
Number of subjects: 607
Study 12766064 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGTS MD
Number of subjects: 607
Study 12766064 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGTS VF score variability
Number of subjects: 607
Study 11194979 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 fentanyl
Number of subjects: 30
Study 11194979 — intervention group
Group type: COMPARATOR
Intervention: 1 microgram.kg‐1 remifentanil
Number of subjects: 30
Study 9375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg IV divided into 3 injections, then 200 mg orally daily for 3 months)
Number of subjects: 131
Study 9375949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9375949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients with signs of CHF)
Number of subjects: 131
Study 1492579 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone solution in almond oil, 2 mg/0.1 ml (total dose approximately 11 mg)
Number of subjects: 20
Study 1492579 — intervention group
Group type: COMPARATOR
Intervention: Progesterone solution in dimethicone, 5 mg/0.1 ml (total dose approximately 28 mg)
Number of subjects: 20
Study 2981088 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17
Study 2981088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31403817 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing (CAMI)
Number of subjects: 296
Study 31403817 — intervention group
Group type: COMPARATOR
Intervention: Standard motivational interviewing (MI)
Number of subjects: 296
Study 30006308 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Diabetes Knowledge for Teachers (TDKT)
Number of subjects: 756
Study 30006308 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions about symptoms and hypoglycaemia treatment
Number of subjects: 756
Study 30006308 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching experience and subject taught
Number of subjects: 756
Study 26142345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (cNRT)
Number of subjects: 0
Study 26142345 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 26142345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 23778343 — intervention group
Group type: EXPERIMENTAL
Intervention: Saint John's wort (300 mg daily for three months)
Number of subjects: 21
Study 21492066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early preventive rehabilitation
Number of subjects: 190
Study 21492066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 18791717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel (175 mg/m², 15 min infusion)
Number of subjects: 35
Study 18791717 — intervention group
Group type: COMPARATOR
Intervention: Taxol (175 mg/m², 3 h infusion)
Number of subjects: 35
Study 18791717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel
Number of subjects: 35
Study 18791717 — intervention group
Group type: COMPARATOR
Intervention: Taxol
Number of subjects: 35
Study 17348991 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% N-acetyl glucosamine (NAG)
Number of subjects: 0
Study 17348991 — intervention group
Group type: COMPARATOR
Intervention: Topical combination of 2% N-acetyl glucosamine (NAG) with 4% niacinamide
Number of subjects: 0
Study 15365622 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 42
Study 15365622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11518072 — intervention group
Group type: COMPARATOR
Intervention: Jarsin 300 (9 tablets)
Number of subjects: 0
Study 11518072 — intervention group
Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 0
Study 11518072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperforin
Number of subjects: 0
Study 11518072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericin
Number of subjects: 0
Study 11518072 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (5‐HT2 receptor antagonist)
Number of subjects: 0
Study 11518072 — intervention group
Group type: COMPARATOR
Intervention: WAY‐100635 (5‐HT1A antagonist)
Number of subjects: 0
Study 11518072 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (DA antagonist)
Number of subjects: 0
Study 7841729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of racemic adrenaline
Number of subjects: 54
Study 7841729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no racemic adrenaline)
Number of subjects: 54
Study 2905636 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac tromethamine
Number of subjects: 96
Study 2905636 — intervention group
Group type: COMPARATOR
Intervention: 400 mg glafenine
Number of subjects: 96
Study 31377215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 62
Study 31377215 — intervention group
Group type: COMPARATOR
Intervention: Sham-mindfulness meditation
Number of subjects: 62
Study 29570376 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (two acquisitions: 35-second delayed CT for chest and 70-second delayed abdominal acquisition)
Number of subjects: 77
Study 29570376 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (single 60-second delayed acquisition covering chest and abdomen)
Number of subjects: 77
Study 29570376 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 77
Study 29570376 — intervention group
Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 77
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 493
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 493
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 493
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 493
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 493
Study 28567698 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 493
Study 28567698 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 493
Study 26416458 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutated patients
Number of subjects: 247
Study 26416458 — intervention group
Group type: COMPARATOR
Intervention: KRAS wild-type patients
Number of subjects: 247
Study 23840296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Ferulate (SF) pretreatment for 14 days with bupropion (150 mg)
Number of subjects: 33
Study 21205368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus tympanostomy tube insertion (n = 25)
Number of subjects: 52
Study 21205368 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy plus myringotomy (n = 27)
Number of subjects: 52
Study 18050282 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Scan+ women (identified by Electrical Impedance Scanning)
Number of subjects: 2141
Study 16476115 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex PIL (Patient Information Leaflet)
Number of subjects: 0
Study 16476115 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple PIL incorporating pictograms
Number of subjects: 0
Study 16476115 — intervention group
Group type: COMPARATOR
Intervention: No PIL (Control group)
Number of subjects: 0
Study 14643034 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg oral misoprostol
Number of subjects: 156
Study 14643034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10923073 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte anion exchange measurement in patients with AD
Number of subjects: 0
Study 10923073 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte anion exchange measurement in age-matched controls
Number of subjects: 0
Study 9024268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta-estradiol orally for 3 months (with 1 mg norethisterone acetate added for 10 days during the last 16 days for endometrial protection)
Number of subjects: 25
Study 9024268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8024294 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (800 micrograms)
Number of subjects: 12
Study 8024294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3305221 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelosuppressive postinduction treatment
Number of subjects: 877
Study 3305221 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly maintenance chemotherapy
Number of subjects: 877
Study 3305221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive two-course preremission therapy
Number of subjects: 877
Study 31518715 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of iodine staining at baseline chromoendoscopy
Number of subjects: 1468
Study 31518715 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on patient age, body mass index, pathology findings, and baseline iodine staining
Number of subjects: 1468
Study 30595271 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPAD
Number of subjects: 65
Study 30595271 — intervention group
Group type: COMPARATOR
Intervention: No RADPAD
Number of subjects: 65
Study 26699899 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (initial dose of 40 mg at admission followed by 10 mg/day for 30 days)
Number of subjects: 0
Study 26699899 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin treatment)
Number of subjects: 0
Study 26121897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 49
Study 26121897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23563500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation initiated 6 weeks after LSF
Number of subjects: 82
Study 23563500 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation initiated 12 weeks after LSF
Number of subjects: 82
Study 21916603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status (serum 25-hydroxyvitamin D < 32 ng/mL)
Number of subjects: 884
Study 21916603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D levels
Number of subjects: 884
Study 18254812 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (Ipsen)
Number of subjects: 12
Study 18254812 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (Allergan)
Number of subjects: 12
Study 18254812 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 16629780 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC)
Number of subjects: 0
Study 16629780 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 14637136 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of GSTT1 and GSTM1 functional alleles
Number of subjects: 41
Study 14637136 — intervention group
Group type: EXPERIMENTAL
Intervention: One functional allele (either GSTT1 or GSTM1)
Number of subjects: 41
Study 14637136 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects matched for age and sex, 27 subjects)
Number of subjects: 41
Study 10757852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 30 days
Number of subjects: 28
Study 10757852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 8666630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 40
Study 8666630 — intervention group
Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 40
Study 8417634 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 10 mg
Number of subjects: 23
Study 8417634 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 20 mg
Number of subjects: 23
Study 8417634 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 40 mg
Number of subjects: 23
Study 8417634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3777463 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic solution with hyaluronidase (75 international units diluted in 5 ml of local anesthetic mixture)
Number of subjects: 100
Study 3777463 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic solution without hyaluronidase
Number of subjects: 100
Study 29558953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (30 g daily for 3 months)
Number of subjects: 91
Study 29558953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g daily for 3 months)
Number of subjects: 91
Study 29911358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac with 0.5% loteprednol
Number of subjects: 80
Study 29911358 — intervention group
Group type: COMPARATOR
Intervention: 0.5% loteprednol alone
Number of subjects: 80
Study 25066102 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with booster program
Number of subjects: 101
Study 25066102 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavior therapy (ICBT) without booster program
Number of subjects: 101
Study 22320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PostC) following percutaneous coronary intervention (PCI)
Number of subjects: 20
Study 22320186 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 20
Study 22320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PostC)
Number of subjects: 20
Study 20084409 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal blockade with 0.5% bupivacaine [10 ml x height (m)]
Number of subjects: 51
Study 20084409 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 51
Study 19453397 — intervention group
Group type: EXPERIMENTAL
Intervention: FluBlok, a recombinant trivalent hemagglutinin vaccine
Number of subjects: 0
Study 19453397 — intervention group
Group type: COMPARATOR
Intervention: Traditional egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study 15935019 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 200 mg
Number of subjects: 47
Study 15935019 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 400 mg
Number of subjects: 47
Study 15935019 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg
Number of subjects: 47
Study 15935019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 12856480 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 10789188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance measurements with 2-liters dialysate volume
Number of subjects: 33
Study 10789188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance measurements
Number of subjects: 33
Study 10789188 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy volunteers)
Number of subjects: 33
Study 8676421 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2I > or = 150 or DO2I > or = 600 mL/min/m2 (Group 1)
Number of subjects: 58
Study 8676421 — intervention group
Group type: COMPARATOR
Intervention: Conventional parameters (Group 2)
Number of subjects: 58